Aptamers for CD Antigens: From Cell Profiling to Activity Modulation

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2017 Mar 23

PMID 28325295

Citations 15

Authors

Amin Nozari

Maxim V Berezovski

Affiliations

Soon will be listed here.

Abstract

Nucleic acid-based aptamers are considered to be a promising alternative to antibodies because of their strong and specific binding to diverse targets, fast and inexpensive chemical synthesis, and easy labeling with a fluorescent dye or therapeutic agent. Cluster of differentiation (CD) proteins are among the most popular antigens for aptamers on the cell surface. These anti-CD aptamers could be used in cell biology and biomedicine, from simple cell phenotyping by flow cytometry or fluorescent microscopy to diagnosis and treatment of HIV/AIDS to cancer and immune therapies. The unique feature of aptamers is that they can act simultaneously as an agonist and antagonist of CD receptors depending on a degree of aptamer oligomerization. Aptamers can also deliver small interfering RNA to silence vital genes in CD-positive cells. In this review, we summarize nucleic acid sequences of anti-CD aptamers and their use, which have been validated in multiple studies.

Citing Articles

Aptamer-engineered (nano)materials for theranostic applications.

Rabiee N, Chen S, Ahmadi S, Veedu R Theranostics. 2023; 13(15):5183-5206.

PMID: 37908725 PMC: 10614690. DOI: 10.7150/thno.85419.

Antitumor efficacy of multi-target vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers.

Proskurina A, Ruzanova V, Ritter G, Efremov Y, Mustafin Z, Lashin S J Biomed Res. 2023; 37(3):194-212.

PMID: 37161885 PMC: 10226083. DOI: 10.7555/JBR.36.20220052.

Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery.

Narwade M, Shaikh A, Gajbhiye K, Kesharwani P, Gajbhiye V Biomater Res. 2023; 27(1):42.

PMID: 37149607 PMC: 10164340. DOI: 10.1186/s40824-023-00365-y.

DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors.

Shishparenok A, Furman V, Zhdanov D Cancers (Basel). 2023; 15(7).

PMID: 37046816 PMC: 10093432. DOI: 10.3390/cancers15072151.

Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future.

Zhang Y, Zhang H, Chan D, Ma Y, Lu A, Yu S Front Cell Dev Biol. 2022; 10:1048148.

PMID: 36393853 PMC: 9664076. DOI: 10.3389/fcell.2022.1048148.

References

Zhu Q, Shibata T, Kabashima T, Kai M . Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur J Med Chem. 2012; 56:396-9. DOI: 10.1016/j.ejmech.2012.07.045. View

Wengerter B, Katakowski J, Rosenberg J, Park C, Almo S, Palliser D . Aptamer-targeted antigen delivery. Mol Ther. 2014; 22(7):1375-1387. PMC: 4089008. DOI: 10.1038/mt.2014.51. View

Boltz A, Piater B, Toleikis L, Guenther R, Kolmar H, Hock B . Bi-specific aptamers mediating tumor cell lysis. J Biol Chem. 2011; 286(24):21896-905. PMC: 3122244. DOI: 10.1074/jbc.M111.238261. View

Sugamura K, Ishii N, Weinberg A . Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004; 4(6):420-31. DOI: 10.1038/nri1371. View

Judge T, Wu Z, Zheng X, Sharpe A, Sayegh M, Turka L . The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol. 1999; 162(4):1947-51. View

Young L, Campling B, Cole S, Deeley R, Gerlach J . Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001; 7(6):1798-804. View

Wang X, Seegmiller A, Reddy N, Li S . CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. Eur J Haematol. 2015; 97(1):39-47. DOI: 10.1111/ejh.12680. View

Abdullah L, Chow E . Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013; 2(1):3. PMC: 3565873. DOI: 10.1186/2001-1326-2-3. View

Dai S, Jia R, Zhang X, Fang Q, Huang L . The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014; 290(1):72-9. DOI: 10.1016/j.cellimm.2014.05.006. View

10.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

11.

Lao Y, Phua K, Leong K . Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano. 2015; 9(3):2235-54. DOI: 10.1021/nn507494p. View

12.

Zhang P, Zhao N, Zeng Z, Chang C, Zu Y . Combination of an aptamer probe to CD4 and antibodies for multicolored cell phenotyping. Am J Clin Pathol. 2010; 134(4):586-93. DOI: 10.1309/AJCP55KQYWSGZRKC. View

13.

Rose-John S, Scheller J, Elson G, Jones S . Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006; 80(2):227-36. DOI: 10.1189/jlb.1105674. View

14.

Berezhnoy A, Stewart C, McNamara 2nd J, Thiel W, Giangrande P, Trinchieri G . Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing. Mol Ther. 2012; 20(6):1242-50. PMC: 3369303. DOI: 10.1038/mt.2012.18. View

15.

Weinberg A . OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 2002; 23(2):102-9. DOI: 10.1016/s1471-4906(01)02127-5. View

16.

Herrmann A, Priceman S, Swiderski P, Kujawski M, Xin H, Cherryholmes G . CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest. 2014; 124(7):2977-87. PMC: 4071407. DOI: 10.1172/JCI73174. View

17.

Ejrnaes M, Filippi C, Martinic M, Ling E, Togher L, Crotty S . Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med. 2006; 203(11):2461-72. PMC: 2118120. DOI: 10.1084/jem.20061462. View

18.

Taylor R, Lindorfer M . Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008; 20(4):444-9. PMC: 2660201. DOI: 10.1016/j.coi.2008.05.011. View

19.

Melero I, Hervas-Stubbs S, Glennie M, Pardoll D, Chen L . Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007; 7(2):95-106. DOI: 10.1038/nrc2051. View

20.

Prodeus A, Abdul-Wahid A, Fischer N, Huang E, Cydzik M, Gariepy J . Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Mol Ther Nucleic Acids. 2015; 4:e237. PMC: 4417124. DOI: 10.1038/mtna.2015.11. View